An integrase inhibitor-based antiretroviral regimen is noninferior to a boosted protease inhibitor-based regimen in treatment ...

Among treatment-naive adults with advanced HIV disease, integrase inhibitors are a preferred first-line therapy over protease inhibitors.

Scientists are testing CRISPR gene editing as a potential HIV cure after successfully removing the virus from infected cells ...

In patients with HIV infection on rifampicin TB therapy, twice-daily bictegravir/emtricitabine/tenofovir alafenamide results ...

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is ...

Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human ...

The efficiency of HIV-1 replication hinges on the dynamic interplay between viral RNA and an array of viral and host proteins. At the core of this process is the dual role of the unspliced viral RNA, ...

– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today ...